Prasugrel: a novel platelet ADP P2Y₁₂ receptor antagonist. A review on its mechanism of action and clinical development

Author： Angiolillo Dominick J Suryadevara Siva Capranzano Piera Bass Theodore A

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.16, 2008-11, pp. : 2893-2900

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Prasugrel, a Novel P2Y 12 Receptor Antagonist, in the Management of Acute Coronary Syndromes

By Baker William L. White C. Michael

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 4, 2009-08 ,pp. : 213-229

Adis International

Access to resources Recommend Favorite

Platelet P2Y 12 Receptor Inhibition: An Update on Clinical Drug Development

By Vivas David Angiolillo Dominick J.

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 217-226

Adis International

Access to resources Recommend Favorite

P2Y 12 ADP receptor antagonists after percutaneous coronary interventions P2Y 12 -ADP-Rezeptorantagonisten nach perkutanen Koronarinterventionen

By Trenk Dietmar

PHARMAKON, Vol. 1, Iss. 1, 2013-01 ,pp. : 53-60

Govi-Verlag

Access to resources Recommend Favorite

Importance of potent P2Y₁₂ receptor blockade in acute myocardial infarction: focus on prasugrel

By Jeong Young-Hoon Tantry Udaya S Gurbel Paul A

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 12, 2012-08 ,pp. : 1771-1796

Informa Healthcare

Access to resources Recommend Favorite

Biology and Pharmacology of the Platelet P2Y12 Receptor

Current Pharmaceutical Design, Vol. 12, Iss. 10, 2006-04 ,pp. : 1255-1259

Bentham Science Publishers

Access to resources Recommend Favorite